International EU27 pharmaceutical production, trade, dependencies and vulnerabilities: a factual analysi

• The EU27 itself is the main export destination of EU pharmaceutical products accounting for most of the value of exports and the US comes in second place. [...] • In Chapter 5, we present a detail analysis of EU27 import dependency and export vulnerability looking at the market concentration of EU27 imports and exports for each of the product and the share of EU27 imports and exports from non-EU countries. [...] In addition, an analysis of the changes in intra and extra-EU exports and imports was done for the year 2020 to explore the potential effects of Covid-19 on the exchange of pharmaceutical products. [...] In terms of the value of exports, Figure 4.2 shows that the share of HMP exports from EU27 that goes to other EU27 countries has been relatively stable during the last ten years and the share going to the US has increased from 12.4% to 18.8%. [...] In terms of the volume of imports for APIs, the EU27 share in EU imports dropped from 60.4% in 2010 to 54.0% in 2019.